CriteriaCaixa relaunches its startup investment arm to support high-potential science and technology startups. The initiative involves two funds—Criteria Bio Ventures and Criteria Venture Tech—to drive growth in emerging companies. CriteriaCaixa commits €300 million to these investments, targeting innovation-driven ventures.
Jul 2026CriteriaCaixaNews article
Cytospire Therapeutics announces Series A financingcytospire.com/cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell-engagers-into-clinical-trials-for-the-treatment-of-can/
Cytospire Therapeutics secures an oversubscribed £61 million ($83 million) Series A funding round to advance its pipeline of first-in-class pan-gamma delta T-cell engagers into clinical trials. The company targets these therapies for cancer treatment, leveraging a novel approach in immunotherapy. Investors demonstrate strong confidence in Cytospire’s innovative platform for developing next-generation cell-based treatments.
Adaptam Therapeutics secures €3 million in funding to develop immunotherapies targeting immunosuppressive myeloid cells in cancer treatment. The company focuses on disrupting tumor microenvironments that hinder immune responses. This funding supports research into novel approaches for enhancing anti-tumor immunity.
Tolerance Bio secures **$20.2 million in seed funding** to develop thymus-targeted therapies for immune-mediated diseases. The company also establishes a **Scientific Advisory Board** to guide its research. Tolerance Bio focuses on extending healthspan by modulating thymus function, a key regulator of immune responses.
Dec 2024Tolerance BioNews article
Criteria Bio Ventures
Criteria Bio Ventures is a venture capital fund that invests in biotechnology and health companies at early and growth stages.
